Siemens Healthineers AG Unsponsored ADR (SMMNY) AI Stock Analysis

• Market Cap: $58.53B
• Dividend Yield: 1.98%
• Average Volume (3M): 1.52K
• Price to Earnings (P/E): 24.8
• Beta (1Y): 1.00
• Revenue Growth: 6.68%
• EPS Growth: 12.49%
• Country: US
• Employees: 72,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.39
• Shares Outstanding: 2,256,000,000
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 1,521
• PEG Ratio: 1.07
• Price to Book (P/B): 3.30
• Price to Sales (P/S): 2.69
• P/FCF Ratio: 33.88
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $28.00
• Price Target Upside: 7.61% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 74 Outperform
• Price Target: $29.00 ▲(11.45% Upside)

Siemens Healthineers AG's strong financial performance and positive earnings call sentiment are the primary drivers of its stock score. Technical analysis suggests a neutral trend with potential overbought conditions, while valuation metrics indicate the stock is fairly valued. The company's strategic initiatives and growth in key segments bolster its outlook, despite challenges in China and macroeconomic headwinds.

Positive Factors

Strategic Partnerships

The collaboration with Telix Pharmaceuticals enhances Siemens Healthineers' capabilities in precision imaging and radiation therapy, potentially improving patient outcomes and expanding market reach in personalized cancer care.

Revenue Growth

Strong revenue growth in key segments like Imaging and Advanced Therapies indicates robust demand and effective market positioning, supporting long-term financial health.

Free Cash Flow Improvement

Improved free cash flow and reduced leverage enhance financial flexibility, enabling strategic investments and sustaining operational resilience.

Negative Factors

Challenges in China

Flat revenue in China due to market challenges could hinder growth prospects in a key region, impacting overall revenue diversification and expansion efforts.

Tariff and Foreign Exchange Headwinds

Tariff and currency headwinds can erode profit margins, posing risks to financial performance and necessitating strategic adjustments to mitigate impacts.

Lower Revenue Guidance

Lower revenue guidance for Q1 2026 suggests potential short-term challenges in maintaining growth momentum, requiring strategic focus to address underlying issues.

Siemens Healthineers AG Unsponsored ADR Business Overview & Revenue Model

Company Description

Siemens Healthineers AG Unsponsored ADR (SMMNY) is a global leader in medical technology and healthcare solutions, providing innovative and high-quality products and services in the fields of imaging, diagnostics, and digital health. The company operates primarily in the healthcare sector, focusing on areas such as imaging systems (including MRI, CT, and ultrasound), laboratory diagnostics, and advanced therapies. Siemens Healthineers aims to enhance patient care by delivering cutting-edge technologies and solutions that improve clinical outcomes and operational efficiency in healthcare settings.

How the Company Makes Money

Siemens Healthineers generates revenue through multiple key streams, primarily from the sale of medical devices and imaging equipment, along with diagnostic products and services. Their Imaging segment, which includes MRI, CT, and ultrasound systems, forms a significant portion of their revenue, driven by demand for advanced imaging solutions in hospitals and clinics. In addition to hardware sales, the company earns revenue through software solutions and digital health applications that enhance medical imaging and diagnostics. Furthermore, Siemens Healthineers provides maintenance services and support for its products, contributing to recurring revenue. The company also engages in strategic partnerships and collaborations with healthcare providers and technology firms, which can lead to joint ventures and co-development of new technologies, thereby expanding their market reach and boosting revenues.

Siemens Healthineers AG Unsponsored ADR Financial Statement Overview

Summary

Siemens Healthineers AG demonstrates strong financial performance with consistent revenue growth, solid profitability margins, and efficient cash flow management. The company's stable balance sheet and effective leverage management further enhance its financial stability, despite a slight increase in debt levels.

Income Statement

Siemens Healthineers AG has demonstrated strong revenue growth with a TTM increase of 3.3% compared to the previous year. The company maintains healthy profitability metrics, with a gross profit margin of 38.76% and a net profit margin of 9.29% in the TTM period. EBIT and EBITDA margins are also robust at 14.48% and 20.02%, respectively, indicating efficient operational management. The consistent improvement in margins and revenue growth suggests a positive trajectory in financial performance.

Balance Sheet

The balance sheet reflects a stable financial position with a debt-to-equity ratio of 0.89, indicating manageable leverage. Return on equity stands at 11.69%, showcasing effective use of shareholder funds to generate profits. The equity ratio is approximately 39.64%, suggesting a solid equity base relative to total assets. While the company maintains a strong equity position, the slight increase in debt levels warrants monitoring.

Cash Flow

Cash flow analysis reveals a strong free cash flow growth rate of 11.10% in the TTM period, highlighting improved cash generation capabilities. The operating cash flow to net income ratio is 1.56, indicating efficient conversion of income into cash. The free cash flow to net income ratio of 0.77 further supports the company's ability to generate cash relative to its earnings. Overall, cash flow metrics suggest robust liquidity and financial flexibility.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	23.38B	25.81B	22.36B	21.68B	21.71B	18.00B
Gross Profit	9.06B	9.97B	8.47B	7.71B	8.14B	6.95B
EBITDA	4.68B	5.06B	4.22B	3.78B	4.26B	3.52B
Net Income	2.17B	2.37B	1.94B	1.51B	2.04B	1.73B
Balance Sheet
Total Assets	44.60B	52.13B	46.05B	46.68B	49.06B	41.93B
Cash, Cash Equivalents and Short-Term Investments	2.37B	2.25B	2.68B	1.64B	1.44B	1.32B
Total Debt	15.70B	17.70B	16.21B	16.65B	16.65B	14.31B
Total Liabilities	26.88B	30.88B	27.81B	28.55B	29.20B	25.87B
Stockholders Equity	17.68B	21.20B	18.20B	18.08B	19.84B	16.04B
Cash Flow
Free Cash Flow	2.62B	2.50B	1.77B	971.00M	1.40B	2.11B
Operating Cash Flow	3.39B	3.40B	2.47B	1.81B	2.26B	2.78B
Investing Cash Flow	-965.00M	-1.00B	-666.00M	-1.07B	-868.00M	-14.14B
Financing Cash Flow	-1.99B	-2.86B	-1.30B	-380.00M	-1.40B	11.99B

Siemens Healthineers AG Unsponsored ADR Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 26.02
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SMMNY, the sentiment is Neutral. The current price of 26.02 is above the 20-day moving average (MA) of 25.44, below the 50-day MA of 26.16, and below the 200-day MA of 26.86, indicating a neutral trend. The MACD of 0.16 indicates Negative momentum. The RSI at 57.16 is Neutral, neither overbought nor oversold. The STOCH value of 88.77 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SMMNY.

Siemens Healthineers AG Unsponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDT	80 Outperform	$124.70B	26.28	9.81%	2.76%	5.34%	13.15%
BSX	79 Outperform	$142.51B	51.41	12.66%	―	21.62%	54.80%
SMMNY	74 Outperform	$58.53B	24.80	11.46%	1.98%	6.68%	12.49%
ABT	73 Outperform	$217.03B	15.66	30.62%	1.88%	6.37%	142.39%
SYK	70 Outperform	$135.66B	46.58	14.04%	0.95%	10.95%	-18.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PHG	50 Neutral	$25.48B	-33.05	―	3.30%	-0.76%	-55.03%

Siemens Healthineers AG Unsponsored ADR Corporate Events

Siemens Healthineers Reports Strong Q3 2025 Results

Siemens Healthineers AG, a leading company in the healthcare sector, specializes in medical technology and offers a wide range of products and services in imaging, diagnostics, and advanced therapies. The company is known for its innovative solutions that enhance patient care worldwide.